Published in:
01-02-2018 | Original Paper
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors
Authors:
Delphine Vezzosi, Christine Do Cao, Ségolène Hescot, Jérôme Bertherat, Magali Haissaguerre, Vanina Bongard, Delphine Drui, Christelle De La Fouchardière, Frédéric Illouz, Françoise Borson-Chazot, Bodale Djobo, Amandine Berdelou, Antoine Tabarin, Martin Schlumberger, Claire Briet, Philippe Caron, Sophie Leboulleux, Rossella Libe, Eric Baudin, For Comete-Cancer Network
Published in:
Discover Oncology
|
Issue 1/2018
Login to get access
Abstract
A partial response (PR) has been proposed as a surrogate for overall survival in advanced adrenocortical carcinoma (ACC). The primary endpoint of the study was to characterize the time until a PR in patients with metastatic ACC treated with a standard therapy is achieved. Long-term survivors were selected to allow evaluation of delayed tumor response to mitotane. Records from patients with metastatic ACC that survived for > 24 months were retrieved. Tumor response was analyzed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Time until a tumor response, after treatment initiation or therapeutic plasma mitotane level, was analyzed. Sixty-eight patients were analyzed. The first-line systemic therapy was mitotane as a monotherapy (M) (n = 57) or cytotoxic polychemotherapy plus/minus mitotane (PC ± M) (n = 11). The second-line therapy was M (n = 2) or PC ± M (n = 41). Thirty-two PRs occurred in 30/68 patients (44.1%): this was obtained for 13 (40.6%) during M and during PC ± M for 19/32 responders (59.4%). PRs were observed within 6 months of starting M or PC ± M in 76.9 and 94.7% of responses, respectively, within 6 months of therapeutic plasma mitotane being first observed in 88.9% of responses with M and in 53.3% of responses with PC ± M. All PRs (but one) occurred within 1 year after initiating treatment. To conclude, Most patients with metastatic ACC and long survival times had PRs within the first 6 months of standard systemic therapy, and almost all within the first year. The absence of response after that period could be considered as a treatment failure. Maintenance of mitotane therapy in non-responders after 1 year should be questioned in future randomized trials.